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INTRODUCTION
Accidental ingestion of paraquat is frequently fatal within
a few days due to multiple-organ failure mediated by reac-
tive oxygen species (ROS) (1). Over the past 30 yr, several
methods for modifying the toxicity of paraquat have been
examined: a) prevention of absorption by the gastrointesti-
nal tract (2, 3), b) removal from the bloodstream (1, 4), c)
prevention of accumulation in the lungs (5, 6), d) scaveng-
ing oxygen free radicals (7), and e) prevention of lung fibro-
sis (8, 9). Unfortunately, most of these methods have not
proven effective, with the outcome already determined by
the degree of exposure to paraquat.
Several sulfur-containing compounds have been examined
as antioxidants in paraquat-induced lung injury due to their
inherent antioxidant properties and an early observation that
depletion of reduced glutathione (GSH) enhanced paraquat
toxicity (10). Even though some studies have shown that
alveolar type II cells can supplement endogenous synthesis
of GSH with the uptake of exogenous GSH (11, 12), the
antioxidant effectiveness of exogenously administered GSH
is hindered by its instability when crossing cell membranes
and its rapid hydrolysis in the circulation (13-15).
In circulation, GSH is degraded rapidly by gamma-glu-
tamyltranspeptidase, an enzyme found on the extracellular
surfaces of cells, yielding glutamate (Glu), cysteine (Cys), and
glycine (Gly) (16). In some cells, degradation of GSH at the
cell surface directly provides the cells with Cys required for
GSH synthesis (17). Although Cys is a critical amino acid
for the synthesis of GSH, it is sufficiently reactive in circu-
lation for large amounts of Cys to be oxidized immediately
to cystine (Cys2).
Recently we found that extracellular methionine (Met) is
as strong an antioxidant as Cys against the intracellular ROS
produced by paraquat. In man, this essential sulfur-contain-
ing amino acid is metabolized in the trans-sulfuration path-
way (18). It is successively converted to S-adenosyl-methio-
nine, S-adenosyl-homocysteine, and homocysteine. Homo-
cysteine lies at a branch point from which sulfur metabolism
can be controlled, either it can be remethylated to Met or
converted to Cys via cystathione. The remethylation of homo-
cysteine is catalyzed by betaine-homocysteine methyltrans-
ferase and 5-methyltetrahydro-folate-homocysteine methyl-
transferase. In this setting, Cys2 has been shown to increase
the activity of betaine-homocysteine methyltransferase (19-
21). In this regard, one of the potential functions of extra-
cellular GSH is a source of both Cys and Met in the overall
sulfur-containing amino acid balance. Aebi et al. (22) reported
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Pharmacokinetics of Glutathione and Its Metabolites in Normal Subjects 
To determine the loading and maintenance dosage of glutathione (GSH) for patients
suffering from reactive oxygen species (ROS) injury such as acute paraquat intoxi-
cation, a kinetic study of reduced GSH was performed in synchrony with that of cys-
teine (Cys), cystine (Cys2), and methionine (Met). Human subject’s porticipitation was
voluntary. The effective dose of Cys, Cys2, and Met against ROS in fibroblast cells
generated by paraquat was assessed using laser scanning confocal microscopy.
Both Cys and Met suppressed ROS in a dose-dependent manner at concentra-
tions of 1-1,000  M; the concentration required to suppress ROS by 50% was 10
M for Cys and 50  M for Met. Using metabolite kinetics with the assumption that
Cys and Met are the metabolites of GSH, expected concentrations of Cys and Met
of above 20 and 50  M were estimated when GSH was administered at 50 mg/kg
body weights every 205.4 min for Cys and 427.4 min for Met. 
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that Cys in plasma increased after the GSH infusion, but the
plasma concentration of Cys plus Cys2 decreases.
Taking together the antioxidant effect of both Cys and Met,
and the metabolic interrelationships between Met, Cys, and
Cys2, we hypothesized that it would be more accurate to
estimate the antioxidant effect of GSH based on the kinetics
of each sulfur-containing amino acid. In order to prove this
hypothesis, we observed the change of sulfur-containing amino
acids concentration in blood, synchronized with the changes
in GSH after the intravenous administration of GSH.
MATERIALS AND METHODS
All of the reagents were obtained from Sigma (St. Louis,
MO, U.S.A.) except where otherwise stated. This experimen-
tal study was approved by the Investigational Review Board
at Soonchunhyang University Cheonan Hospital (Cheonan,
Korea), and all human subjects provided written informed
consent, and their participation was voluntary. Subjects ate
a regular diet without alcohol and did not have any kinds of
drugs including vitamins, for more than 3 days before the
study.
Cell culture
Swiss 3T3 fibroblasts, obtained from American Type Cul-
ture Collection (ATCC CCL 92), were maintained at 37℃
in Dulbecco’s modified Eagle’s medium supplemented with
25 mM HEPES (pH 7.4), 10% (v/v) fetal bovine serum, 100
units/mL penicillin, and 100 mg/mL streptomycin. For experi-
ments, cells were cultured on round coverslips in 12-well
plates and then stabilized for 30 min with Dulbecco’s mod-
ified Eagle’s medium supplemented with 5 mg/mL apotrans-
ferrin, 1 mg/mL bovine serum albumin, 25 mM HEPES
(pH 7.4), 2 mM glutamine, 100 units/mL penicillin, and
100 mg/mL streptomycin (serum-free medium).
Measurement of intracellular ROS
The amount of intracellular ROS was measured as described
in Koo et al. (23). Cultured cells on round coverslips were
stabilized in serum-free medium without phenol red for at
least 30 min, and then stimulated with paraquat for varying
durations.
ROS generation in cells was assessed using the probe 2,7-
dichlorofluorescein (DCF) (Molecular Probes, Eugene, OR,
U.S.A.). Some of the cells were treated with various concen-
trations of antioxidants (GSH, Cys, Cys2, and Met) for 30
min prior to imaging. For the last 5 min of stimulation, the
membrane-permeable diacetate form of the DCF: was added
to the perfusate at a final concentration of 5  M. Esterases
within the cell cleave the acetate groups on DCF-diacetate,
thus trapping the reduced probe intracellularly. Intensity values
(confocal laser scanning microscope, LSM 510, Carl Zeiss,
Germany) are reported relative to initial values after subtract-
ing the background. In preliminary experiments, paraquat
at 50-500  M produced ROS in Swiss 3T3 fibroblasts in a
dose-dependent manner at 30-60 min. The cells detached
within 30 min when the paraquat concentration was over
600  M, or when the incubation time was over 60 min at
lower concentrations. Therefore, we selected the optimal con-
dition for our experiments to be 40 min of incubation with
500 M  paraquat.
Blood sampling for GSH and amino acids in volunteers
GSH (50 mg per kg of body weight, L-glutathione, reduced;
Dong-A Pharmaceutical, Seoul, Korea) was infused into an
antecubital vein over 10 min. Blood samples started from 6
o’clock in the morning after 12 hr overnight fasting through
an indwelling intravenous catheter placed on other side of
cubital vein, just before GSH administration (for basal level
at time zero) and at 10, 20, 30, 60, 90, 120 and 240 min
after GSH administration in seven male volunteers (medical
students, aged 22 or 23 yr; body weight 65.5±4.5 kg). Dur-
ing the sampling, only water drinking was permitted. No
side effect has observed after glutathione infusion. 
Basal blood cell count, urinalysis and blood chemistry in-
cluding BUN, creatinine, liver function test, and fasting blood
sugar were normal in the all subjects. They ate a regular diet
without alcohol and did not take any drugs including vita-
mins for at least 3 days before the study.
Serum GSH measurement
Samples were prepared and derivatized for HPLC analysis
using procedures (with slight modifications) as described
previously (24, 25). Briefly, 0.1 mL of serum was mixed with
0.1 mL of 25 mM dithiothreitol and 0.05 mL of 0.1 M Tris
(pH 8.5) for the measurement of total GSH. The GSH-o-
phthalaldehyde adducts were separated on a 4.6×250 mm
Luna C18 column (5  m, Phenomenex, Torrance, CA, U.S.A.)
using two Waters 510 pumps, a 717 autosampler, and a 474
fluorescence detector (Milford, MA, U.S.A.), and fluorescence
was detected at 420 nm with excitation at 340 nm. The amo-
unt of oxidized glutathione (GSSG) was obtained by subtract-
ing the amount of GSH from the amount of total GSH.
Serum amino acid measurement
Glu, Cys, Cys2, Met, and Gly were analyzed using the
Pico-Tag method (Waters, Milford, MA, U.S.A.) after the
serum was dried in a sample tube under vacuum (Korea Basic
Science Institute, Daejeon, Korea) (26). Free-amino-acid sam-
ples were derived using derivatizing solution (ethanol:dis-
tilled H2O:triethylamine:phenylisothiocyanate at 7:1:1:1,
v/v/v/v) for 15 min. The derivatized free amino acids werePharmacokinetics of Glutathione 723
applied to a 30-cm Pico-Tag free-amino-acid-analysis column
(3.9×300 mm) equilibrated with buffer A equipped with
a Waters HPLC system (510 HPLC pump, 717 automatic
sampler, 996 photodiode array detector, and Millennium 32
chromatography manager) and eluted with a linear gradient
composed of buffer B (0%, 14%, 20%, 46%, and 100%) at
a flow rate of 1 mL/min at 46℃. The absorbance at 254 nm
was measured. Buffer A was 140 mM sodium acetate (6%
acetonitrile), and buffer B was 60% acetonitrile.
Statistical analysis
Results are expressed as mean±SD unless stated otherwise.
Intracellular ROS was measured in about 30 cells randomly
selected from three separate experiments, and DCF fluores-
cence intensities of treated cells were compared with those
of unstimulated control cells. Analysis of variance was used
to detect differences in ROS between groups, and statistical
significance was defined as a probability value of p<0.05.
The pharmacokinetics of GSH, GSSG, and total GSH were
characterized by the peak plasma concentration (Cmax), elim-
ination half time (t1/2), and the area under the plasma concen-
tration-time curve (AUC) for the first 60 min (BA Calc 2002,
KFDA, Ver 1.1.1). The elimination rate constant (ke) was
determined by linear-regression analysis of the log-linear part
of the concentration-time curve. The value of t1/2 was calcu-
lated as t1/2=ln (2/k). The AUC was calculated by the log-linear
trapezoidal rule from 0 to 60 min after subtraction of the
basal concentration. In order to avoid the influence of endoge-
nous GSH, two concentrations (obtained at 120 and 240 min)
were not included in calculating pharmacokinetic parameters
because of the values less than basal level. The loading dose
was calculated as the desired plasma level×volume of dis-
tribution at steady state, and the infusion rate as the desired
plasma level×clearance (volume/unit time).
RESULTS
Effect of GSH, Cys, Cys2, and Met on the intensity of
ROS in Swiss 3T3 fibroblasts
Our preliminary study found that Swiss 3T3 fibroblasts
had a good reproducibility in both the production and the
suppression of ROS, each done by paraquat and by antioxi-
dants respectively. GSH at concentrations of 1-10 mM sup-
pressed ROS in a dose-dependent manner, with 50% sup-
pression was done by 5 mM GSH (Fig. 1A). Each of Cys,
Fig. 1. Effect of glutathione, cysteine and methinine on the pro-
duction of ROS by paraquat in Swiss 3T3 fibroblasts. (A) 10 mM
of GSH suppressed ROS in dose dependant pattern. Complete
suppression of ROS was observed at 5 mM of GSH. (B) Cys at
1-1,000  M suppressed the production of ROS in a dose-depen-
dent manner. Software quantification of the signal intensities pro-
duced the following values: 2.50±0.31 in paraquat group, 2.25
±0.22 in 1  M Cys, 1.30±0.17 in 10  M Cys, and 1.20±0.15
in 100  M Cys. Complete suppression was observed at 1,000  M
Cys. (a) and (b) denote statistically significant differences in com-
parison with control (a) and (b) paraquat groups, respectively. (C)
Met at 1-1,000  M suppressed the production of ROS in a dose-
dependent manner. Software quantification of the signal intensi-
ties produced the following values: 2.50±0.31 in paraquat group,
2.40±0.30 in 1  M Met, 2.05±0.25 in 10  M Met, 1.19±0.15 in 100  M Met, and 1.05±0.12 in 1,000  M Met. (a) and (b) denote sta-




GSH 2 mM GSH 5 mM GSH 10 mM
GSH 1 mM Paraquat 500  M
Control
Met 10  M (a, b) Met 100  M (b) Met 1,000  M (b)
Met 1  M (a) Paraquat 500  M (a)
Control
Cys 10  M (a, b) Cys 100  M (a, b) Cys 1,000  M (b)
Cys 1  M (a) Paraquat 500  M (a)Cys2, and Met was observed to suppress ROS at various con-
centrations in dose-dependent manner: GSH at 1-10 mM,
both Cys and Met at 1-1,000  M, and Cys2 at 40-400  M
as shown in Fig. 1. 50% of the suppression was done by 5
mM GSH (Fig. 1A), by 10  M Cys, 50  M Met (Fig. 1B,
C), and by 400  M of Cys2 (data are not presented in figure).
Pharmacokinetics of GSH, Cys, Cys2, and Met
The basal and peak plasma concentrations of GSH, GSSG,
and total GSH following the infusion of GSH (50 mg per kg
of body weight) are listed in Table 1. The elimination rate
constants, the elimination half-life, the systemic clearance,
and the apparent volumes of GSH, GSSG, and total GSH
following the infusion of GSH are listed in Table 2. It is pos-
tulated that at the lowest effective plasma GSH concentration
is 1 mM. Assuming this as the target concentration, the opti-
mal dose of GSH can be determined from the pharmacoki-
netic parameters as follows. The loading dose (1.69 g/kg) was
calculated by multiplying the volume of distribution admin-
istered by the target concentration. The optimal infusion rate
was calculated by multiplying the target concentration by
the clearance rate, and was 5.70 g/hr/kg. Because GSH has a
very short half-life (of 10 min), it is difficult to maintain it
at a therapeutic concentration.
Changes in the metabolites of GSH were presented in Table
1. Glu and Cys reached their peak concentrations at 10 min,
and Met at 20 min. However, Cys2 increased gradually, peaked
at 30 min, and then slowly decreased. The 10- and 20-min
concentrations of Glu, Cys, and Met were significantly higher
than their baseline values, but no significant change was ob-
served in Cys2. The repeated ANOVA revealed statistically
significant nonlinear relations between concentration and
time for all four amino acids. The pharmacokinetic profile
of Cys after subtracting the baseline concentration was sum-
marized in Table 2. Using metabolite kinetics whilst assum-
ing that Cys is a metabolite of GSH, and that AUC (Cys)single i.v.
is 4108.4  M ∙ min after administering GSH at 50 mg per
kg of body weight, the expected Cys concentration is over
20  M when this dose is given every 205.4 min. In the same
way, when it comes to Met, the concentration is over 50  M
when the same dose is given every 427.4 min.
DISCUSSION
The intracellular ROS produced by paraquat was suppressed
by extracellular GSH at concentrations of 1-10 mM (Fig.
1A). This concentration range is three orders of magnitude
higher than normal extracellular levels because the GSH
concentration in circulation has known to be  M range. After
intravenous administration, in agreement with a previous
report (25), most of the GSH was oxidized to GSSG and dis-
appeared immediately from circulation with a half-life of
about 10 min. Pharmacokinetic investigations revealed that
GSH at a loading dose of 1.69 g/kg and a maintenance dosage
of 5.70 g/hr/kg are needed to reach 1 mM GSH which is a
minimum requirement of extracellular concentration to sup-
press significantly the intracellular ROS. Considering that
it is impossible to administer such a large amount of GSH
in practical point of view, the intravenous administration of
GSH would be an invalid treatment modality if GSH does
not metabolized furthermore to other substances carrying
antioxidant capacity.
In our study, five amino acids were measured over time:
Glu, Cys, and Gly as metabolites of GSH, and Cys2 and Met
as sulfur-containing compounds in plasma. Glu, Gly, and
Cys reached peak concentrations at 10 min, Met peaked at
20 min, and Cys2 at 30 min. This finding suggests that GSH
administered intravenously degraded immediately into the
three amino acids. The intravenous infusion of GSH at 50
mg per kg of body weight increased the concentration of Cys
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Time (min) 0 240 120 60 30 20 10
GSH 4.3 154.4 11.1 5.3 4.7 4.0 5.7
(2.5) (70.0) (7.3) (2.9) (2.6) (2.3) (2.7)
GSSG 9.7 1061.5 144.4 62.3 18.6 11.8 12.0
(6.8) (481.2) (60.0) (26.8) (5.3) (5.3) (7.4)
Total GSH 14.0 1219.8 155.4 67.6 23.3 15.8 16.8
(12.1) (628.4) (53.7) (29.4) (9.8) (7.0) (8.1)
Glu 47.4 268.0 191.3 121.0 38.4 53.3 31.9
(14.3) (78.8) (19.6) (30.7) (16.5) (19.4) (11.4)
Cys 11.4 264.7 64.6 42.2 26.7 15.0 10.6
(2.5) (58.5) (10.1) (9.3) (3.9) (3.5) (3.0)
Cys2 57.0 68.8 81.5 103.6 95.6 88.0 71.1
(8.4) (10.5) (8.4) (11.1) (11.6) (13.0) (11.8)
Met 25.4 362.2 377.7 198.0 103.4 87.8 64.1
(2.7) (40.5) (64.1) (36.6) (14.7) (22.6) (18.6)
Gly 220 477 455 314 271 193 216
(23) (101) (112) (93) (81) (80) (41)
Table 1. Changes of amino acids and GSH during the observa-
tion period, in mean (SD) concentration (in  M) after intravenous





















Mean 4.3 150 1242.8 0.07 10.9 309.2 5.528
SD 5.5 234.6 1905.2 0.026 3.3 360.9 6.935
GSSG
Mean 9.7 1055.8 11148.1 0.066 10.8 10.6 0.164
SD 6.8 480.1 3705 0.012 2 3.7 0.061
Total glutathione
Mean 14 1205.8 12427 0.066 10.9 9.8 0.152
SD 12.1 621.7 4618.3 0.014 2.2 3.8 0.058
Table 2. Pharmacokinetic parameters of GSH, GSSG and total
GSH following high-dosage intravenous administration of GSH
(50 mg per kg of body weight) in 7 volunteersto over 20  M, which suppressed intracellular ROS by approx-
imately 50% for about 60 min. Using metabolite kinetics
with the assumption that Cys is a metabolite of GSH, Cys
concentration over 20  M would be achieved when GSH
were administered at 50 mg/kg body weights every 205.4
min. In the same way, the Met concentration of 50  M, which
suppresses intracellular ROS by about 50%, would be achieved
if GSH were administered at 50 mg per kg of body weights
every 427.4 min.
Occasionally, the result of in vitro study used to be chal-
lenged when it is going to be extended to that of in vivo,
because of the uncertainty of whether the results from in vitro
experiment is also true in vivo. In that sense, our study raises
fundamental questions to be answered. First of all, there may
be difference in the intensity of ROS formation by paraquat
and/or in ROS suppression by antioxidant, between in vitro
cell line and cells in physiologic state. This is one of the sub-
jects frequently argued in vitro study, which has to be over-
come by a careful interpretation of other adjunct experiments.
In this regard, our results that derived from the in vitro exper-
iments and being extended to the in vivo experiments should
be understood as relative ones rather than absolute ones, even
the data are presented in numbers. The other problem is that
in vitro and in vivo have the quite different metabolism sys-
tem of GSH and amino acids.
The purpose of our current study was to find out how we
could determine the appropriate dose of GSH for the patients
with critical ROS injury such as acute paraquat intoxication.
Our study just observed the epiphenomenon of sulfa-contain-
ing amino acid without intensive check-up on each amino
acid metabolism respectively. During the initial 30 min after
administration, the Cys2 level increased slowly and thereafter
it decreased. The Met concentrations were higher than basal
levels during the first 30 min and decreased as the Cys2
decreased (Fig. 1C). This implies that the increase in Cys2
stimulated Met synthesis. As we mentioned above the cur-
rent study is not designed to determine the metabolic inter-
relationship among sulfur-containing amino acids. However,
keeping in mind that methylation of homocysteine is an
essential pathway to the formation of Met, it seems likely
that GSH metabolites influence the enzymes involved in
Met synthesis.
The remethylation of homocysteine is catalyzed by betaine-
homocysteine methyltransferase and 5-methyltetrahydro-
folate-homocysteine methyltransferase. In this setting, Cys2
is known to increase the activity of betaine-homocysteine
methyltransferase-this is the so-called Cys2-sparing effect of
Met, which is readily observed when Cys2 is added to a low-
Met diet in animal models (20). Therefore, it seem reasonable
that practical guidelines for the dosage of GSH should be
derived from pharmacokinetic studies of sulfur-containing
amino acids synchronized with the changes in GSH after the
intravenous administration of GSH.
In conclusion, not being conclusive, our results provide
us relevant clinical information. GSH is a useful antioxidant
for the patients suffering from acute, critical injury mediated
by ROS, and the recommended dose appears to be determined
more reasonably when the metabolite of GSH is encountered.
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